Cancer Treatment and Research Communications, 2023 Purpose: The objective of this study was to describe filgrastim biosimilar-Sandoz modalities of use in patients receiving cytotoxic chemotherapy regimens with a rest period of ≤14 days and to investigate the incidence of febrile neutropenia (FN) in ...
Jean-Marc Phelip +6 more
doaj +1 more source
South Asian Journal of Cancer, 2021 Methods This is a retrospective study. G-CSF was administered in the dose of 10 μg/kg subcutaneous as a single dose for 4 days. On day 5, peripheral blood stem cell (PBSC) apheresis was performed using Haemonetics MCS plus or COBE Spectra apheresis ...
Sadik Husian +6 more
doaj +1 more source
A Randomised, Blinded, Placebo-Controlled, Dose Escalation Study of the Tolerability and Efficacy of Filgrastim for Haemopoietic Stem Cell Mobilisation in Patients With Severe Active Rheumatoid Arthritis [PDF]
, 1998 Autologous haemopoietic stem cell transplantation (HSCT) represents a potential therapy for severe rheumatoid arthritis (RA). As a prelude to clinical trails, the safety and efficacy of haemopoietic stem cell (HSC) mobilisation required investigation as ...
Biggs, J. C. +7 more
core +1 more source
Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research. [PDF]
, 2017 Acute ischemic stroke is a devastating cause of death and disability, consequences of which depend on the time from ischemia onset to treatment, the affected brain region, and its size.
Akyol, Onat +6 more
core +3 more sources
Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report
Current Problems in Cancer: Case ReportsIntroduction: Filgrastim is recommended to be used 24–72 h after the last dose of chemotherapy for the prophylaxis of febrile neutropenia. However, several studies demonstrate the efficacy and safety of the use of filgrastim within the same day of the ...
Suluck Soontaros +2 more
doaj +1 more source
Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors [PDF]
, 2017 The World Marrow Donor Organization recommends original granulocyte-colony stimulating factor (G-CSF) for the mobilization of stem cells in healthy unrelated hematopoietic stem cell donors. We report the comparison of a biosimilar G-CSF (Zarzio) with two
Bogusz, K +10 more
core +1 more source
Clinical and Translational Science, 2020 Acute exposure to high doses of radiation leads to severe myelosuppression, but few treatments are currently available to treat hematopoietic syndrome of acute radiation syndrome.
John Harrold +6 more
doaj +1 more source
Filgrastim-induced cutaneous vasculitis in a patient undergoing stem cell mobilization
Iraqi Journal of HematologyNeupogen (filgrastim), a granulocyte colony-stimulating factor, is widely utilized for the management of chemotherapy-induced neutropenia and as part of mobilization regimens for hematopoietic stem cell transplantation.
Ghada H. Alani
doaj +1 more source
International Journal of Cancer, EarlyView.What's New? Uveal melanoma is the most common primary intraocular cancer in adults, and up to half of patients develop metastatic disease, predominantly in the liver, where prognosis remains poor despite promising treatment options. In this study, the authors evaluated the safety and efficacy of administering systemic therapy within 40 days of liver ...
Patrick Kasteleiner +4 more
wiley +1 more source
The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma [PDF]
, 2010 Background: The use of chemotherapy regimens with moderate or high risk of febrile neutropenia (defined as having a FN incidence of 10% or more) and the respective incidence and clinical management of FN in breast cancer and NHL has not been studied in ...
Gerlier, Laetitia +13 more
core +2 more sources